TITLE

New approaches to rewarding pharmaceutical innovation

AUTHOR(S)
Grootendorst, Paul; Hollis, Aidan; Levine, David K.; Pogge, Thomas; Edwards, Aled M.
PUB. DATE
April 2011
SOURCE
CMAJ: Canadian Medical Association Journal;4/5/2011, Vol. 183 Issue 6, p681
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers information on the new patent approaches for pharmaceutical drug innovation. It mentions the proposed mechanisms which includes push programs, which is the public funding of basic research and clinical trials, and pull programs which include royalty-based schemes and reward-based schemes to develop the pharmaceutical current systems. It also discusses the limitations of the drug patent system, alternatives and complements to patents, and implementation of the issues.
ACCESSION #
60158601

 

Related Articles

  • INDUSTRY UPDATE - Lymphoma.  // PharmaWatch: Cancer;June 2003, Vol. 2 Issue 6, p8 

    No abstract available.

  • Developing New Drugs in 1000 Days. Gugliotti, Jan // Applied Clinical Trials;Aug2002, Vol. 11 Issue 8, p44 

    Explores the implications of the speed and capacity in clinical trials of the U.S. competitive pharmaceutical industry for drug development. Innovation-driven improvement in clinical development time; New drug application approval time; Good laboratory practice. INSETS:...

  • Overhauling clinical trials. Scott, Christopher Thomas; Baker, Monya // Nature Biotechnology;Mar2007, Vol. 25 Issue 3, p287 

    The article examines the designs of clinical trials that adapt midstream which are billed as a cure for challenges in drug development. Drug companies do not apply adaptive designs to individual projects but spread them across their portfolios. The United States Food and Drug Administration...

  • Double Dip: Doctors Paid to Advise, Promote Drug Companies That Fund Their Research. Ornstein, Charles; Jones, Ryann Grochowski // Pro Publica;3/1/2014, p12 

    The article focuses on the stronger relationship between pharmaceutical companies and physicians in the U.S. It notes the willingness of pharmaceutical companies to pay for physicians who conduct their clinical trials and give speeches on behalf of their drugs. It also mentions the criticism of...

  • Drug companies must report clinical trial results, even when they won't lead to a product.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p157 

    The article reports on the need for drug companies performing clinical trials to disclose the results of their research, even if they do not longer pursue product development.

  • SECTION INDEX.  // Monthly Prescribing Reference;Oct2016, Vol. 32 Issue 10, pA24 

    The section index in the journal which features different disorders and their treatments is presented.

  • No end to European evolution? O'Donnell, Peter // Applied Clinical Trials;Dec2003, Vol. 12 Issue 12, p53 

    Discusses the efforts of the European Union to update its pharmaceutical rules in 2003. Outcome of the major review conducted by the European Agency for the Evaluation of Medicinal Products; Goal of implementing the rules by May 2004; Details of the proposed legislative changes in the extensive...

  • R&D UPDATE: Lung Cancer.  // PharmaWatch: Cancer;February 2003, Vol. 2 Issue 2, p5 

    Reports on developments of drugs for lung cancer treatment in the U.S. as of January 2003. Delay of the decision of the U.S. Food and Drug Administration (FDA) regarding the priority review of the new Iressa drug requested by AstraZeneca PLC; Announcement of the result of the phase I/II...

  • NEWS HEADLINES: Lymphoma.  // PharmaWatch: Cancer;June 2003, Vol. 2 Issue 6, p24 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics